• Hua Medicine’s Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China

    Hua Medicine’s Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China
    October 10, 2022 newsmistry
    0 Comment
    Uncategorized

    SHANGHAI, CHINA, Oct 10, 2022 – (ACN Newswire) – Hua Medicine (the “Company”, HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications…
    Read More

    Uncategorized
    Uncategorized

    Leave a Reply

    Your email address will not be published. Required fields are marked *